AVXL — Anavex Life Sciences Share News
0.000.00%
Last trade - 00:00- $106.60m
- -$11.72m
Brief: Anavex Life Sciences Files For Common Stock Offering Of Up To $150 Million - SEC Filing
Brief: Anavex Life Sciences Extends Employment Agreement With CEO Christopher Missling
Anavex Life Sciences Corp reports results for the quarter ended March 31 - Earnings Summary
Anavex Life Sciences Corp expected to post a loss of 15 cents a share - Earnings Preview
Anavex Life Sciences Corp reports results for the quarter ended December 31 - Earnings Summary
Anavex Life Sciences Corp expected to post a loss of 17 cents a share - Earnings Preview
Brief: Anavex Life Sciences Announces Peer-Reviewed Publication Of Oral Blarcamesine Phase Iib/Iii Data In The Journal Of Prevention Of Alzheimer’S Disease
Brief: New Phase IIB/III Clinical Data Demonstrates Over Three Years Of Continuous Treatment With Oral Blarcamesine To Significantly Benefit Early Alzheimer’S Disease Patients
U.S. RESEARCH ROUNDUP-Apple, EverQuote, UnitedHealth
Brief: Anavex Life Sciences Announces Acceptance Of Peer-Reviewed Manuscript
Brief: Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results From Ongoing Phase 2 Study Of ANAVEX®3-71 For The Treatment Of Schizophrenia
Anavex Life Sciences Corp reports results for the quarter ended in June - Earnings Summary
Anavex Life Sciences Corp expected to post a loss of 16 cents a share - Earnings Preview
Brief: Anavex Life Sciences Terminates A&R Sales Agreement Dated May 1, 2020
Brief: Anavex Life Sciences Corp Files For Stock Shelf Of Up To $150 Million – SEC Filing
Primary Endpoint, ADCS-ADL Did Not Reach Significance At Week 48
Brief: Anavex Life Sciences Announces Expansion Of Leadership Team
Anavex Life Sciences Corp reports results for the quarter ended in March - Earnings Summary
Anavex Life Sciences Corp expected to post a loss of 11 cents a share - Earnings Preview